465 related articles for article (PubMed ID: 27172220)
21. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
22. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
[TBL] [Abstract][Full Text] [Related]
23. CXCR7 and CXCR4 Expressions in Infiltrative Astrocytomas and Their Interactions with HIF1α Expression and IDH1 Mutation.
Bianco AM; Uno M; Oba-Shinjo SM; Clara CA; de Almeida Galatro TF; Rosemberg S; Teixeira MJ; Nagahashi Marie SK
Pathol Oncol Res; 2015 Apr; 21(2):229-40. PubMed ID: 24970694
[TBL] [Abstract][Full Text] [Related]
24. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
25. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
26. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
[TBL] [Abstract][Full Text] [Related]
27. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
[TBL] [Abstract][Full Text] [Related]
28. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
[TBL] [Abstract][Full Text] [Related]
29. Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.
Náger M; Santacana M; Bhardwaj D; Valls J; Ferrer I; Nogués P; Cantí C; Herreros J
Cell Cycle; 2015; 14(22):3644-55. PubMed ID: 26654598
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
Kim BYS; Jiang W; Beiko J; Prabhu SS; DeMonte F; Gilbert MR; Sawaya R; Aldape KD; Cahill DP; McCutcheon IE
J Neurooncol; 2014 Jun; 118(2):405-412. PubMed ID: 24777756
[TBL] [Abstract][Full Text] [Related]
31. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
32. MET gain in diffuse astrocytomas is associated with poorer outcome.
Pierscianek D; Kim YH; Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Wrede K; Nakazato Y; Tanaka Y; Mariani L; Vital A; Sure U; Ohgaki H
Brain Pathol; 2013 Jan; 23(1):13-8. PubMed ID: 22672415
[TBL] [Abstract][Full Text] [Related]
33. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
Mott RT; Turner KC; Bigner DD; McLendon RE
J Neurosurg; 2008 Feb; 108(2):330-5. PubMed ID: 18240930
[TBL] [Abstract][Full Text] [Related]
34. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
Abd El-Hafez A; Ismail Hany HSED
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
[TBL] [Abstract][Full Text] [Related]
35. Molecular pathogenesis of pediatric astrocytic tumors.
Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
[TBL] [Abstract][Full Text] [Related]
36. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
37. Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas.
Mäkelä K; Nordfors K; Finne J; Jokilammi A; Paavonen T; Haapasalo H; Korja M; Haapasalo J
BMC Cancer; 2014 Aug; 14():623. PubMed ID: 25164322
[TBL] [Abstract][Full Text] [Related]
38. [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].
Dong L; Pu PY; Wang H; Wang GX; Kang CS; Jiao DR
Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):232-6. PubMed ID: 16776982
[TBL] [Abstract][Full Text] [Related]
39. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
Snuderl M; Fazlollahi L; Le LP; Nitta M; Zhelyazkova BH; Davidson CJ; Akhavanfard S; Cahill DP; Aldape KD; Betensky RA; Louis DN; Iafrate AJ
Cancer Cell; 2011 Dec; 20(6):810-7. PubMed ID: 22137795
[TBL] [Abstract][Full Text] [Related]
40. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Ohno M; Narita Y; Miyakita Y; Okita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Kayama T; Shibui S
Brain Tumor Pathol; 2012 Oct; 29(4):183-91. PubMed ID: 22790483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
